BioAge LabsvsMerck & Company

BIOA and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

BioAge Labs (BIOA) has a market value of $226M and Merck & Company (MRK) $354B. Over the last year, with dividends, BIOA moved -34.6% and MRK +58.8%. Dividend yield: BIOA none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BIOA$226M

    MRK$354B

    MRK is 1,566 times BIOA

  • Revenue, 12 months

    BIOA$8.6M

    MRK$67.4B

    MRK is 7,836 times BIOA

  • Net income, 12 months

    BIOA-$108M

    MRK$2.5B

  • Operating margin

    BIOA-1,401.8%

    MRK–

  • ROIC

    BIOA-28.7%

    MRK3.9%

    32.6 points apart

  • P/E

    BIOA–

    MRK144.5

  • Dividend yield

    BIOA0.0%

    MRK2.4%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BIOA-34.6%

MRK+58.8%

100200300DecFebAprJunAugOct
Returns by period
PeriodBIOAWith dividendsMRKWith dividends
1 year since November 14, 2025-34.6%Price -34.6%+58.8%Price +54.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BIOABioAge LabsMRKMerck & Company

Valuation

BIOAMRK
Valuation
Price$5.10$143.37
Market value$226M$354B
Enterprise value (EV)–$399B
P/E–144.5
P/E, 5-year median–14.8
P/B0.77.9
EV/EBIT–83.7
Free cash flow yield–4.2%

Results and growth

BIOAMRK
Results and growth
Revenue, 12 months$8.6M$67.4B
Net income, 12 months-$108M$2.5B
Free cash flow, 12 months-$103M$14.7B
Earnings per share, 12 months-$2.55$0.98
Revenue growth, year on year–1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

BIOAMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-1,401.8%–
Net margin-1,253.6%3.6%
ROIC-28.7%3.9%
ROE-32.7%5.2%

Balance sheet

BIOAMRK
Balance sheet
Cash$284M$9.7B
Total debt$2.7M$53.8B
Net debt / EBITDA–5.7
Interest cover-913.2×2.4×

Dividends and buybacks

BIOAMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BIOA or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, BioAge Labs or Merck & Company?

By market value, Merck & Company ($354B) is about 1,566.1 times BioAge Labs ($226M), at today's prices.

How did BIOA and MRK stock do over the last 1 years?

Since November 14, 2025, BIOA's price moved -34.6% and MRK's +54.3%. With dividends: BIOA -34.6% (-34.6% a year), MRK +58.8% (+58.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, BIOA or MRK?

The dividend yield at today's price is none for BioAge Labs and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, BioAge Labs or Merck & Company?

Over the last twelve months, the net margin was -1,253.6% for BioAge Labs and 3.6% for Merck & Company, and the operating margin -1,401.8% and –. Revenue was $8.6M and $67.4B.

Which is the better investment, BioAge Labs or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.